Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13195429 | 0.78 | IRAK4 (0.34) | IRAK4PRMT5WDR77MKNK2MKNK1 | |
| SCHEMBL15833488 | 0.75 | MAPK13 (0.39) | MKNK2GLO1ALDH1A1 | |
| SCHEMBL13195335 | 0.74 | MKNK2 (0.40) | IRAK4PRMT5WDR77MKNK2MTNR1A | |
| SCHEMBL16968009 | 0.73 | DUT (0.42) | IRAK4PRMT5WDR77MKNK2GLO1 | |
| SCHEMBL15833690 | 0.72 | MTNR1A (0.36) | IRAK4PRMT5WDR77MKNK2MTNR1A | |
| Ammonia Solution, Strong SCHEMBL27463691 | 0.72 | PI4KA (0.39) | IRAK4PRMT5WDR77MKNK2MKNK1 | |
| SCHEMBL13194201 | 0.72 | IRAK4 (0.36) | IRAK4PRMT5WDR77MKNK2 | |
| SCHEMBL25818492 | 0.71 | MKNK2 (0.40) | IRAK4PRMT5WDR77MKNK2MTNR1A | |
| SCHEMBL2173797 | 0.71 | MKNK2 (0.40) | PRMT5WDR77MKNK2MTNR1AMKNK1 | |
| SCHEMBL5068124 | 0.71 | MKNK2 (0.42) | PRMT5WDR77MKNK2MKNK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218172-A1 | Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors | PFIZER LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218172-A1 | Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors | MUSK, DMPK, TPM3 | IRAK4 995/4885PRMT5 817/4885WDR77 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.